Global investment firm The Riverside Company has invested in Avance Clinical, an Australian contract research organisation, while Israel’s EasySend raised $50.5 million in funding.
The Riverside Company invests in Australia’s Avance Clinical
Global investment firm The Riverside Company has invested an undisclosed amount in Avance Clinical (Avance), an Australian contract research organisation (CRO) for international biotech firms, according to an announcement.
The amount of the investment was not disclosed and Avance said the funding will further support the expansion of its clinical trial business.
“With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions,” said CEO Yvonne Lungershausen.
Avance provides global regulatory standard clinical research services across all phases to the local and international biopharma industry. It has been accredited to expand into clinical trials for vaccines and GMO therapies.
Israeli startup EasySend scores $50.5m in Series B funding
Aside from the Series B funding, which was also participated by Vertex IL, Intel Capital, and Hanaco Ventures, EasySend said it also secured $5 million in venture debt from Silicon Valley Bank.
Founded in 2016 by CEO Tal Daskal, COO Omer Shirazi, and CTO Eran Shirazi, EasySend’s platform allows enterprises and SMEs to build and launch digital customer journeys, including customer applications, onboarding questionnaires, and claims forms, in days.
The company said its platform utilises a no-code builder that is cloud-based and leverages AI, third-party integrations, and analytics to provide seamless customer experiences.